- Home
- MRSN
as 05-20-2024 4:00pm EST
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 319.4M | IPO Year: | 2017 |
| Target Price: | $5.57 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.80 - $9.62 | Next Earning Date: | 05-09-2024 |
| Revenue: | $38,298,000 | Revenue Growth: | 18.40% |
| Revenue Growth (this year): | 4.3% | Revenue Growth (next year): | -22.03% |
Share on Social Networks:
Stock Insider Trading Activity of Mersana Therapeutics Inc. (MRSN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bala Mohan | MRSN | SVP, Chief Development Officer | Jan 13 '24 | Sell | $2.71 | 3,431 | $9,298.01 | 14,052 | SEC Form 4 |
| Lowinger Timothy B | MRSN | SVP, Chief Sci.&Tech. Officer | Jan 13 '24 | Sell | $2.71 | 10,409 | $28,208.39 | 199,329 | SEC Form 4 |
| Protopapas Anna | MRSN | Director | Jan 13 '24 | Sell | $2.71 | 29,399 | $79,671.29 | 125,153 | SEC Form 4 |
| Mandelia Ashish | MRSN | VP, Chief Accounting Officer | Jan 13 '24 | Sell | $2.71 | 5,025 | $13,617.75 | 23,328 | SEC Form 4 |
| Carvajal Alejandra | MRSN | SVP, Chief Legal Officer | Jan 13 '24 | Sell | $2.71 | 4,381 | $11,872.51 | 27,403 | SEC Form 4 |
| Bala Mohan | MRSN | SVP, Chief Development Officer | Oct 25 '23 | Sell | $1.13 | 1,912 | $2,160.56 | 8,733 | SEC Form 4 |
Latest Mersana Therapeutics Inc. News
MRSN Breaking Stock News: Dive into MRSN Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Insider Monkey
10 days ago
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript
GuruFocus.com
10 days ago
Mersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed Analysis
Zacks
11 days ago
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates
GlobeNewswire
11 days ago
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
GlobeNewswire
17 days ago
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
18 days ago
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
Zacks
a month ago